Prostaglandin D2: the end of a story or just the beginning?

Tremendous progress has been made in the treatment of asthma over the past decade. The development of monoclonal antibodies against IgE, interleukin-5 (IL-5) or its receptor, or the IL-4 receptor in particular has been a game changer, for a selected group of patients. These biologics all target the allergic or type 2 side of the spectrum of asthma, but even within the severe allergic or type 2 high asthma population these drugs do not completely prevent exacerbations, reducing their frequency by around 40–60%. Additionally, they must be administered intravenously or subcutaneously, and are costly. In short, there are multiple reasons for expanding the range of treatment options for patients with severe asthma. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trialsAlthough neither trial showed a statistically significant reduction in asthma exacerbations after adjusting for multiple testing, consistent and modest reductions in exacerbations rates were observed in both studies with the 450 mg dose of fevipiprant. Full-Text PDF